Ropes & Gray advised Novo Nordisk in a collaboration with Replicate Bioscience to develop treatments using Replicate’s self-replicating RNA (srRNA) novel platform for obesity, type 2 diabetes and other cardiometabolic diseases. The transaction was announced on August 28.
Under the agreement, Novo Nordisk and Replicate will collaborate on certain targets for cardiometabolic diseases. Novo Nordisk will receive a defined, exclusive, worldwide license to use Replicate’s srRNA technology to develop and commercialize the lead programs. Replicate will receive research funding and is eligible to receive up to $550 million. Replicate is also eligible to receive tiered royalties on future product sales as part of the multi-year deal.
The Ropes & Gray team included life sciences licensing partner Hannah England and life sciences licensing associates Ian Nilsen and Ben Ellington.
Attorneys
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.